BioPharma Resources

Investigational drug · Phase 3

Telitacicept

Also called: RC18, RC18-L

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

8

7 still active

All registered trials

57

Any phase or sponsor naming "Telitacicept"

First trial start

2023

Mar 28, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Telitacicept", any sponsor or status.

Conditions studied

As listed on its trial records.

  • CTD-ILD
  • Primary Sjogren's Disease
  • Sjögren's Disease
  • Generalized Myasthenia Gravis
  • Myasthenia Gravis, Ocular
  • Immunoglobulin A Nephropathy (IgAN)
  • Complement 3 Glomerulopathy (C3G)
  • IC-MPGN
  • Primary IgA Nephropathy
  • Myasthenia Gravis, Generalized

Approved drugs for the same conditions: Myasthenia gravis · IgA nephropathy · Neurology · Immunology and inflammation · Kidney and urology · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Telitacicept" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 317 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.